secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started
------------------------------------------------------------------------------

- Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.
- Cash $789.6M as of June 30, 2024; runway into Q1 2028.
- First patient dosed in APG777 Phase 2 trial; 16-week proof-of-concept data expected 2H2025.
- APG808 interim Phase 1 data Q4 2024; APG990 Phase 1 trial accelerated to Q3 2024.
- Added APG333 (anti-TSLP) to pipeline; entering clinic in 2025; combinations planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/0001104659-24-088029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/tm2421302d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer